NEOANTIGENICS
Neoantigenics is a liability company that focuses on developing oncology theranostics. These neoantigens are uniquely expressed in a wide range of urogenital tract cancers – ovarian, uterine, bladder, and renal cancers – as well as certain other solid cancers such as aggressive stages of pancreatic cancer and many head-and-neck cancers. It was founded in 2012 and headquartered in Charlottesville, Virginia.
NEOANTIGENICS
Industry:
Biotechnology Health Care Health Diagnostics
Founded:
2012-01-01
Address:
Charlottesville, Virginia, United States
Country:
United States
Website Url:
http://www.neoantigenics.com
Total Employee:
1+
Status:
Active
Contact:
434-984-9723
Email Addresses:
[email protected]
Total Funding:
2.54 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Google Maps GoDaddy DNS GStatic Google Static Content Google Maps API GoDaddy
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Element Genomics
Element Genomics is a biotechnology company that focuses on genomics and diagnostics.
Founder
Investors List
IrishAngels
IrishAngels investment in Seed Round - Neoantigenics
Virginia Venture Partners
Virginia Venture Partners investment in Seed Round - Neoantigenics
Official Site Inspections
http://www.neoantigenics.com
Unable to get host informations!!!
More informations about "Neoantigenics"
Neoantigenics - Crunchbase Company Profile & Funding
Neoantigenics is a liability company that focuses on developing oncology theranostics. These neoantigens are uniquely expressed in a wide range of urogenital tract cancers – ovarian, …See details»
Neoantigenics Company Profile 2024: Valuation, Funding
Developer of therapeutic and diagnostic products designed to treat urogenital tract cancers. The company's products are founded on the science around oocyte associated cancer proteins as …See details»
U.Va. Spinoff Neoantigenics Announces Collaboration with ... - Pfizer
Jan 28, 2014 · Neoantigenics LLC, a new biotechnology company founded on discoveries made by Dr. John Herr at the University of Virginia School of Medicine, announced today it has …See details»
Neoantigens: promising targets for cancer therapy
Jan 6, 2023 · Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell …See details»
A comprehensive proteogenomic pipeline for neoantigen …
Oct 11, 2024 · To address this, we present an end-to-end clinical proteogenomic pipeline, called NeoDisc, that combines state-of-the-art publicly available and in-house software for …See details»
Update on Tumor Neoantigens and Their Utility: Why It’s Good To …
Perhaps one of the most important types of mutations that influence anti-tumor immunity is the neoantigen, i.e. a non-self-antigen that arises as a result of somatic mutation. Recent work has …See details»
Identification of neoantigens for individualized therapeutic cancer ...
Feb 1, 2022 · We present a new classification of neoantigens, distinguishing between guarding, restrained and ignored neoantigens, based on how they confer proficient antitumour immunity …See details»
Cancer Neoantigens: Challenges and Future Directions for
Mar 3, 2022 · Neoantigens are tumor-specific proteins that allow the immune system to recognize and destroy a tumor. Cancer immunotherapies, such as personalized cancer vaccines, …See details»
Comprehensive analysis of neoantigens derived from structural …
Jul 17, 2023 · Analysis of 2528 whole genomes reveals that SVs significantly contribute to the neoantigen repertoire in both quantity and quality. Whereas most neoantigens are patient …See details»
Personalized neoantigen cancer vaccines: current progression ...
Sep 26, 2024 · Tumor neoantigens possess specific immunogenicity and personalized therapeutic vaccines based on neoantigens which have shown promising results in some clinical trials, …See details»
U.Va. Spinoff Neoantigenics Announces Collaboration with ... - Pfizer
In addition to scientific engagement between Neoantigenics and Pfizer’s scientific teams, Pfizer is making an equity investment in Neoantigenics through the Pfizer Seed Fund, which supports …See details»
Designing neoantigen cancer vaccines, trials, and outcomes
Neoantigen vaccines are based on epitopes of antigenic parts of mutant proteins expressed in cancer cells. These highly immunogenic antigens may trigger the immune system to combat …See details»
Neoantigen vaccine platforms in clinical development: …
Several neoantigen vaccine platforms are currently being evaluated in early phase clinical trials including the synthetic long peptide (SLP), RNA, dendritic cell (DC), and DNA vaccine platforms.See details»
The landscape of neoantigens and its clinical ... - ScienceDirect
Jan 1, 2024 · Neoantigen is a kind of protein made by cancer cells through the “non-synonymous mutation” process that only affects the malignant cells (Peng et al., 2019, Xu et al., 2020). …See details»
U.Va. Spinoff Neoantigenics Announces Collaboration with Pfizer ...
Jan 28, 2014 · Neoantigenics LLC, a new biotechnology company founded on discoveries made by Dr. John Herr at the University of Virginia School of Medicine, announced today it has …See details»
Targeting public neoantigens for cancer immunotherapy - Nature
May 17, 2021 · Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients’ tumors. However, immunotherapeutic …See details»
Frontiers | Cancer Neoantigens: Challenges and Future Directions …
Mar 2, 2022 · Neoantigens are tumor-specific proteins that allow the immune system to recognize and destroy a tumor. Cancer immunotherapies, such as personalized cancer vaccines, …See details»
Genomic prediction of neoantigens: immunogenomics before NGS
May 14, 2021 · Elaine Mardis highlights a publication that served as a fundamental source of inspiration for the field of immunogenomics, setting the stage for neoantigen discovery.See details»
Sensitive identification of neoantigens and cognate TCRs in
Nov 15, 2021 · In this study, we developed NeoScreen, an in vitro TIL expansion and screening methodology that aims at optimizing the sensitivity of antigen validation and also isolating rare …See details»
Evolutionary dynamics of neoantigens in growing tumors
Sep 14, 2020 · In this study, we used stochastic modeling to study how the clonal structure and immunological phenotype of growing tumors is shaped by negative selection in response to …See details»